Head-to-head · WeighScore
Lttl vs Sumbare Wellness
The verdict
Lttl takes it — 66.1/100 to 61.9/100.
Lttl grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Lttl (pronounced 'little') is a direct-to-consumer telehealth brand offering compounded semaglutide and tirzepatide, a low-dose 'microdose' line, and longevity peptides.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Lttl | Sumbare Wellness |
|---|---|---|
| WeighScore | 66.1/100 | 61.9/100 |
| Grade | C | C |
| Scorecard rank | #204 | #281 |
| Semaglutide | $199/mo (all doses, compounded) | $199/mo (all doses, compounded) |
| Tirzepatide | $279/mo (all doses, compounded) | $199/mo (all doses, compounded) |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #204 · C
Strengths
- Publishes the full price matrix — every medication, form and commitment length — on a public /plans page before checkout
- Flat dose pricing: 'Same price at every dose,' so moving to a higher dose does not raise the monthly bill
- States plainly that its compounded GLP-1s 'are not FDA-approved and have not been evaluated by the FDA for safety, efficacy, or quality'
- Microdose line prices low-dose semaglutide or tirzepatide at $149/mo month-to-month for people sensitive to side effects
- Oral ODT semaglutide offered for members who want to avoid injections
Where it loses points
- Partner pharmacies are never named — the site refers only to 'a partner U.S. pharmacy' (a material disclosure gap for a YMYL purchase)
- The advertised 'Plans start at $129/mo' is the 12-month prepay rate; true month-to-month is $199 semaglutide and $279 tirzepatide
- No public list of states served — eligibility depends on where unnamed 'partner providers are licensed'
- Site banner promises 'Prescribed and shipped within 48 hours' while the shipping policy states 2-5 business days to process plus 3-7 to deliver
- Medications cannot be returned or refunded once they ship from the pharmacy
Graded #281 · C
Strengths
- One flat $199/month price covering medication, provider review and shipping, with no consultation fee and no dose-change surcharge
- Charges nothing if a provider does not approve you
- Offers a deliberate low-dose microdosing protocol aimed at body composition, which most competitors do not break out
- Publishes a named legal entity, a US mailing address and a working phone number
- Pre-screening quiz is short and asks your goal before any medical question
Where it loses points
- Cancellation terms contradict three ways: the homepage says cancel anytime, the Terms say 48 hours notice, the FAQ says 30 days
- Availability is unclear: the homepage counter reads 3 states while the treatment pages say telehealth nationwide, and no state list is published
- Its chart cites placebo-controlled trials of compounded semaglutide and tirzepatide, which do not exist; those trials studied the branded drugs
- No compounding pharmacy is named, and neither 503A nor 503B appears anywhere on the site
- Any returned prescription is charged a $35 disposal fee, and prescription orders cannot be cancelled at all after 24 hours
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.